DTE vs PRLD
DTE (DTE) versus Prelude Therapeutics Inc (PRLD) — a side-by-side from cached financials, not a winner call.
DTE (DTE) common stock.
Prelude Therapeutics Inc (PRLD) is a biotechnology company listed on NASDAQ.
DTE does not have a complete income-statement cache yet.
Latest reported PRLD revenue for 2025-09-30 was $6.5M. Net income was -$83.0M. Revenue was up 116.7% from 2024-09-30 to 2025-09-30. PRLD currently screens at market cap $346.5M.
DTE currently screens at market cap $0. PRLD currently screens at market cap $346.5M.
Not investment advice. Open the DTE and PRLD stock pages for the full models.
Not investment advice.